O Shaughnessy Asset Management LLC Increases Holdings in DexCom, Inc. (NASDAQ:DXCM)

O Shaughnessy Asset Management LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 31.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 957 shares of the medical device company’s stock after purchasing an additional 229 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in DexCom were worth $409,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ameritas Investment Company LLC bought a new stake in DexCom during the first quarter valued at $27,000. Arkadios Wealth Advisors boosted its stake in DexCom by 58.5% during the second quarter. Arkadios Wealth Advisors now owns 65 shares of the medical device company’s stock valued at $27,000 after buying an additional 24 shares during the period. Parkside Financial Bank & Trust boosted its stake in DexCom by 140.7% during the second quarter. Parkside Financial Bank & Trust now owns 65 shares of the medical device company’s stock valued at $28,000 after buying an additional 38 shares during the period. CX Institutional boosted its stake in DexCom by 155.6% during the second quarter. CX Institutional now owns 69 shares of the medical device company’s stock valued at $29,000 after buying an additional 42 shares during the period. Finally, Meridian Wealth Partners LLC boosted its stake in DexCom by 58.3% during the first quarter. Meridian Wealth Partners LLC now owns 95 shares of the medical device company’s stock valued at $34,000 after buying an additional 35 shares during the period. Institutional investors own 96.29% of the company’s stock.

NASDAQ DXCM opened at $565.13 on Friday. DexCom, Inc. has a 1-year low of $305.63 and a 1-year high of $567.81. The company has a current ratio of 5.78, a quick ratio of 5.25 and a debt-to-equity ratio of 0.86. The stock has a 50-day moving average of $501.50 and a 200-day moving average of $422.93. The firm has a market cap of $54.68 billion, a PE ratio of 107.64, a price-to-earnings-growth ratio of 14.59 and a beta of 0.77.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 29th. The medical device company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.33. DexCom had a return on equity of 16.17% and a net margin of 24.45%. The company had revenue of $595.10 million during the quarter, compared to analyst estimates of $548.02 million. As a group, equities research analysts forecast that DexCom, Inc. will post 2.46 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on DXCM shares. SVB Leerink lifted their price objective on DexCom from $485.00 to $500.00 and gave the company an “outperform” rating in a research note on Friday, July 30th. Canaccord Genuity lifted their price objective on DexCom from $455.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, July 30th. Oppenheimer lifted their price objective on DexCom from $500.00 to $525.00 and gave the company an “outperform” rating in a research note on Friday, July 30th. Wells Fargo & Company lifted their price target on DexCom from $380.00 to $475.00 and gave the stock an “equal weight” rating in a research note on Friday, July 30th. Finally, Morgan Stanley lifted their price target on DexCom from $410.00 to $510.00 and gave the stock an “equal weight” rating in a research note on Monday, August 2nd. Two equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $506.25.

In related news, Director Jay S. Skyler sold 20,000 shares of the business’s stock in a transaction dated Tuesday, June 22nd. The stock was sold at an average price of $426.37, for a total transaction of $8,527,400.00. Following the transaction, the director now owns 900 shares in the company, valued at approximately $383,733. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction dated Wednesday, September 15th. The shares were sold at an average price of $540.58, for a total value of $3,243,480.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 61,076 shares of company stock worth $29,228,939. 0.52% of the stock is owned by company insiders.

About DexCom

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.

See Also: Quick Ratio

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.